Kevin J Duffy

List of Publications by Year
in descending order

33	3,157	304602 22	395590 33
papers	citations	h-index	g-index

36	36	36	4630
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	STING Activation and its Application in Immuno-Oncology. Current Topics in Medicinal Chemistry, 2019, 19, 2205-2227.	1.0	11
2	Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature, 2018, 564, 439-443.	13.7	505
3	Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factorâ€“Prolyl Hydroxylase Inhibitor for Anemia. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 336-347.	1.3	65
4	Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury. Journal of Clinical Investigation, 2014, 124, 2396-2409.	3.9	150
5	Targeting Lactate Dehydrogenase-A Inhibits Tumorigenesis and Tumor Progression in Mouse Models of Lung Cancer and Impacts Tumor-Initiating Cells. Cell Metabolism, 2014, 19, 795-809.	7.2	411
6	Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer & Metabolism, 2013, 1, 19.	2.4	163
7	Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury. American Journal of Physiology - Renal Physiology, 2012, 302, F1172-F1179.	1.3	104
8	Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat. Journal of Cardiovascular Pharmacology, 2010, 56, 147-155.	0.8	84
9	Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295. ACS Medicinal Chemistry Letters, 2010, 1, 30-34.	1.3	54
10	Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4350-4353.	1.0	43
11	Synthesis and biological activity of heteroaryl 3-(1,1-dioxo-2H-(1,2,4)-benzothiadizin-3-yl)-4-hydroxy-2(1H)-quinolinone derivatives as hepatitis C virus NS5B polymerase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4354-4358.	1.0	24
12	Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist. Stem Cells, 2009, 27, 424-430.	1.4	243
13	Biochemical Characterization of Human Prolyl Hydroxylase Domain Protein 2 Variants Associated with Erythrocytosis. Biochemistry, 2008, 47, 11165-11167.	1.2	23
14	Novel ATP-Competitive Kinesin Spindle Protein Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 4939-4952.	2.9	73
15	THE DISCOVERY OF ELTROMBOPAG, AN ORALLY BIOAVAILABLE TpoR AGONIST. , 2007, , 241-254.		8
16	GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia.. Blood, 2007, 110, 510-510.	0.6	5
17	3-(1,1-Dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, Potent Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. Journal of Medicinal Chemistry, 2006, 49, 971-983.	2.9	157
18	Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Experimental Hematology, 2005, 33, 85-93.	0.2	176

#	Article	IF	Citations
19	A Highly Efficient, Asymmetric Synthesis of Benzothiadiazine-Substituted Tetramic Acids:â€‰ Potent Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. Organic Letters, 2005, 7, 5521-5524.	2.4	36
20	Species Specificity and Receptor Domain Interaction of a Small Molecule TPO Receptor Agonist.. Blood, 2004, 104, 2909-2909.	0.6	20
21	Discovery of SB-497115, a Small-Molecule Thrombopoietin (TPO) Receptor Agonist for the Treatment of Thrombocytopenia.. Blood, 2004, 104, 2910-2910.	0.6	15
22	Biological Activity and Selectivity for Tpo Receptor of the Orally Bioavailable, Small Molecule Tpo Receptor Agonist, SB-497115.. Blood, 2004, 104, 2912-2912.	0.6	11
23	Resistance Profile of a Hepatitis C Virus RNA-Dependent RNA Polymerase Benzothiadiazine Inhibitor. Antimicrobial Agents and Chemotherapy, 2003, 47, 3525-3530.	1.4	95
24	Selective Binding and Oligomerization of the Murine Granulocyte Colony-stimulating Factor Receptor by a Low Molecular Weight, Nonpeptidyl Ligand. Journal of Biological Chemistry, 2003, 278, 9426-9434.	1.6	15
25	Arresting Initiation of Hepatitis C Virus RNA Synthesis Using Heterocyclic Derivatives. Journal of Biological Chemistry, 2003, 278, 16602-16607.	1.6	65
26	Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-dependent RNA Polymerase. Journal of Biological Chemistry, 2002, 277, 38322-38327.	1.6	190
27	Identification of a Pharmacophore for Thrombopoietic Activity of Small, Non-Peptidyl Molecules. 2. Rational Design of Naphtho[1,2-d]imidazole Thrombopoietin Mimics. Journal of Medicinal Chemistry, 2002, 45, 3576-3578.	2.9	53
28	Identification of a Pharmacophore for Thrombopoietic Activity of Small, Non-Peptidyl Molecules. 1. Discovery and Optimization of Salicylaldehyde Thiosemicarbazone Thrombopoietin Mimics. Journal of Medicinal Chemistry, 2002, 45, 3573-3575.	2.9	83
29	Hydrazinonaphthalene and Azonaphthalene Thrombopoietin Mimics Are Nonpeptidyl Promoters of Megakaryocytopoiesis. Journal of Medicinal Chemistry, 2001, 44, 3730-3745.	2.9	106
30	Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin K. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1907-1910.	1.0	17
31	Total Synthesis of Altohyrtin A (Spongistatin 1): Part 1. Angewandte Chemie - International Edition, 1998, 37, 187-190.	7.2	130
32	A novel synthesis of 2-(2-quinoxalino)-3,5-diarylfurans. Tetrahedron Letters, 1998, 39, 8017-8020.	0.7	7
33	The scope and mechanism of a novel synthesis of 3,4-fused isoxazoles. Journal of the Chemical Society Chemical Communications, 1995, , 2457.	2.0	8